Janux Therapeutics (NASDAQ:JANX) Upgraded at Lifesci Capital

Lifesci Capital upgraded shares of Janux Therapeutics (NASDAQ:JANX - Free Report) to a strong-buy rating in a research note released on Friday,Zacks.com reports.

Other equities research analysts also recently issued research reports about the company. Scotiabank raised their price objective on Janux Therapeutics from $42.00 to $62.00 and gave the company a "sector perform" rating in a research report on Wednesday, December 4th. BTIG Research lifted their price objective on shares of Janux Therapeutics from $82.00 to $100.00 and gave the stock a "buy" rating in a research report on Tuesday, December 3rd. William Blair reiterated an "outperform" rating on shares of Janux Therapeutics in a research note on Tuesday, December 3rd. Cantor Fitzgerald restated an "overweight" rating and issued a $200.00 target price on shares of Janux Therapeutics in a research note on Wednesday, December 11th. Finally, Stifel Nicolaus upped their price target on Janux Therapeutics from $70.00 to $115.00 and gave the stock a "buy" rating in a research report on Tuesday, December 3rd. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Janux Therapeutics has an average rating of "Buy" and a consensus price target of $89.90.

Janux Therapeutics Trading Down 1.9 %

Shares of JANX traded down $1.07 during midday trading on Friday, reaching $54.10. 492,668 shares of the stock were exchanged, compared to its average volume of 1,551,955. The company has a market capitalization of $2.84 billion, a P/E ratio of -46.24 and a beta of 3.29. Janux Therapeutics has a 52 week low of $7.79 and a 52 week high of $71.71. The company's 50 day moving average is $54.43 and its two-hundred day moving average is $47.46.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The business had revenue of $0.44 million for the quarter, compared to the consensus estimate of $1.50 million. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The company's revenue for the quarter was down 82.6% on a year-over-year basis. On average, sell-side analysts expect that Janux Therapeutics will post -1.35 EPS for the current year.

Insider Activity

In other news, CEO David Alan Campbell sold 25,000 shares of the business's stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $53.54, for a total value of $1,338,500.00. Following the completion of the transaction, the chief executive officer now owns 282,054 shares of the company's stock, valued at $15,101,171.16. The trade was a 8.14 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Ra Capital Management, L.P. bought 1,200,000 shares of the company's stock in a transaction that occurred on Friday, October 18th. The shares were bought at an average cost of $44.75 per share, for a total transaction of $53,700,000.00. Following the completion of the acquisition, the director now owns 9,317,246 shares of the company's stock, valued at $416,946,758.50. This trade represents a 14.78 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 92,801 shares of company stock valued at $5,174,735. Company insiders own 29.40% of the company's stock.

Institutional Trading of Janux Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Plato Investment Management Ltd increased its holdings in Janux Therapeutics by 18.7% in the 3rd quarter. Plato Investment Management Ltd now owns 1,186 shares of the company's stock worth $54,000 after acquiring an additional 187 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Janux Therapeutics by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company's stock worth $87,000 after purchasing an additional 339 shares in the last quarter. Amalgamated Bank raised its position in shares of Janux Therapeutics by 61.1% in the second quarter. Amalgamated Bank now owns 970 shares of the company's stock valued at $41,000 after buying an additional 368 shares during the last quarter. Virtu Financial LLC raised its holdings in Janux Therapeutics by 48.0% in the 3rd quarter. Virtu Financial LLC now owns 7,463 shares of the company's stock valued at $339,000 after acquiring an additional 2,419 shares during the last quarter. Finally, Zacks Investment Management increased its holdings in shares of Janux Therapeutics by 8.7% in the third quarter. Zacks Investment Management now owns 42,133 shares of the company's stock valued at $1,914,000 after purchasing an additional 3,360 shares during the last quarter. Institutional investors and hedge funds own 75.39% of the company's stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.